Depixus® is developing its MAGNA™ platform to unlock dramatic new insights into the largely unmined richness of the “dynamic genome” by detecting changes beyond the four-base sequences of DNA and RNA, paving the way to revolutionise molecular diagnostics and drug development.
Depixus® is a life science tools company developing a state-of-the-art platform technology uniquely capable of mining a rich seam of new information from the “dynamic genome”, with significant commercial potential in clinical diagnostics and translational research.
MAGNA™ combines multimodal analytical capability with low sample input requirements to detect minute signals associated with native molecules of DNA, RNA and protein, enabling Depixus® and its partners to dive deeper into biology, delivering new insights into health and disease, whilst advancing the development of a new generation of diagnostics and therapeutics.
Stay up to date with news from Depixus® and our team. Read our latest press releases, blog, the scientific conferences we will be participating in, upcoming webinars and latest job announcements.
3-5 impasse Reille, 75014 Paris,
France
Harston Mill Royston RD Harston
Cambridge CB22 7GG, UK
